The genetic toxicology of 5-bromodeoxyuridine in mammalian cells

S M Morris1

  • 1Department of Health and Human Services, U.S. Public Health Service, Food and Drug Administration, National Center for Toxicological Research, Jefferson, AR 72079.

Mutation Research
|September 1, 1991
PubMed

Insights

The thymidine analog, bromodeoxyuridine (BrdUrd), triggers genetic toxicology responses like mutations and fragile sites. Its cellular effects are explained by proposed DNA incorporation mechanisms.

Area of Science:

  • Genetic Toxicology
  • Molecular Biology
  • Genomics

Background:

  • Bromodeoxyuridine (BrdUrd) is a thymidine analog with significant biological effects.
  • These effects include induction of sister chromatid exchanges (SCE), mutations, toxicity, and fragile site expression in the human genome.

Purpose of the Study:

  • To elucidate the mechanisms underlying the biological responses induced by BrdUrd exposure.
  • To evaluate proposed pathways for BrdUrd's genotoxic and cellular effects.

Main Methods:

  • Review and analysis of experimental evidence on BrdUrd's biological effects.
  • Examination of proposed molecular mechanisms involving BrdUrd incorporation into DNA.

Main Results:

  • BrdUrd induces various genetic and cellular responses, including SCE, mutations, and fragile sites.
  • Two primary mechanisms for BrdUrd's action were initially proposed: incorporation opposite deoxyguanosine or adenosine.

Conclusions:

  • Despite sophisticated new techniques, experimental data strongly support the original proposed mechanisms for BrdUrd's genotoxicity.
  • BrdUrd exerts its effects on eukaryotic cells through pathways consistent with early genotoxicity models.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Other Unique Bacteria01:18

Other Unique Bacteria

Magnetic bacteria exhibit a directed movement called magnetotaxis, driven by structures called magnetosomes. These magnetosomes consist of chains of magnetic particles made of either magnetite (Fe₃O₄) or greigite (Fe₃S₄) and are organized in a linear conformation by a protein scaffold within invaginations of the cell membrane. The bacteria align along the north–south magnetic field lines, much like a compass needle. They are typically microaerophilic or anaerobic and are commonly found near the...